Did you know that asthma affects around 300 million individuals all over the world, with approximately 5 percent of those people suffering from a severe form of this lung disease? They genuinely endure a horrific fight on a daily basis to acquire adequate air, which is accompanied by a large number of symptoms, including coughing, chest tightness, terror, and frequent visits to the hospital. In a recent clinical study that was conducted in phase four, the medication that was tested showed encouraging outcomes. Benralizumab, a protein antibody that possesses the ability to decrease the number of eosinophils, which are immune cells that are responsible for inflammation and are generated in excessive quantities in severe asthma cases, was found to be really helpful. How could this help asthma-diagnosed patients?
Discover the full story below.
Patients controlled on benralizumab can have meaningful reductions in ICS therapy while maintaining asthma control, explained David Jackson, an immunobiologist at King’s College.
During the course of the clinical study that involved more than two hundred patients from all across Europe, Benralizumab proved to be so successful that an astounding ninety-two percent of them were able to safely reduce their usage of oral steroids, with over sixty percent of them no longer requiring them at all. Even more remarkable is the fact that by the time the experiment was over, over ninety percent of the patients who were in the group that had their steroid levels reduced did not experience any exacerbations. Impressive!
With caution, the researchers point out that these encouraging findings are only applicable to a particularly particular kind of asthma. Individuals who have severe eosinophilic asthma and do not respond as well to benralizumab are likely to require extensive steroid therapy still. The only participants who were evaluated were those who reacted well to the substance.
As a result of this clinical trial, which discovered the monoclonal antibody therapy known as benralizumab, those who have severe asthma are one step closer to receiving better relief. It is possible to lessen the requirement for more hazardous high-dose steroid therapies significantly. There is still a need for other research.
